Medtronic Plc (2M6.DE) Q3 2025 Earnings Report

Medtronic delivered a solid QQ3 2025 performance with a revenue base of $8.292 billion, up 4.76% year-over-year and down 1.32% sequentially. The quarter featured margin resilience, with gross margin of approximately 66.5% and operating margin near 19.85%, translating into an operating income of $1.646 billion and net income of $1.294 billion ($1.01 per share). EBITDA reached $2.401 billion, supporting a robust cash profile despite a high absolute debt level. Free cash flow was $2.096 billion, underpinning continued capital return and strategic flexibility.

From a balance sheet perspective, Medtronic remains highly levered, with total debt of $26.607 billion and net debt of about $25.367 billion, against cash and short-term investments of $7.922 billion. The company generated $2.57 billion of operating cash flow and invested approximately $0.476 billion in capital expenditures, yielding strong free cash flow generation and substantial room for R&D investment and acquisitions if desired. The payout ratio stood at 69.3%, with a dividend yield of roughly 0.78%.

Looking ahead, Medtronic continues to navigate a macro environment characterized by hospital capital expenditure cyclicality and currency headwinds, while pursuing growth through portfolio diversification (Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes Operating Unit), productivity initiatives, and digital/remote-monitoring initiatives. Key risks include reimbursement dynamics, competitive intensity in high-growth device categories, and potential volatility in FX. The QQ3 results reinforce a valuation case supported by consistent cash generation, albeit with leverage necessitating a disciplined approach to capital allocation.